Patricia M. Adams
Keine laufenden Positionen mehr
Profil
Patricia M.
Adams formerly worked at Durata Therapeutics, Inc., as Senior Director-Human Resources, ANI Pharmaceuticals, Inc., as Vice President-Human Resources, Naurex, Inc., as Vice President-Human Resources, and Aptinyx, Inc., as Vice President-Human Resources & Administration.
Ms. Adams received her graduate degree from Loyola University of Chicago.
Ehemalige bekannte Positionen von Patricia M. Adams
| Unternehmen | Position | Ende |
|---|---|---|
| DURATA THERAPEUTICS INC | Personalreferent | - |
| APTINYX | Verwaltungsdirektor | - |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Personalreferent | - |
| ANI PHARMACEUTICALS, INC. | Personalreferent | - |
Ausbildung von Patricia M. Adams
| Loyola University of Chicago | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ANI PHARMACEUTICALS, INC. | Health Technology |
| APTINYX | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
Durata Therapeutics, Inc.
 Durata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL. | Health Technology |
